Clodlip treatment depletes multiple myeloid subsets that support T-ALL growth at hematopoietic and nonhematopoietic sites. (A) Quantification of the number of myeloid cells of the indicated subsets in the spleens of control and clodlip-treated leukemic mice transplanted with primary LN3 T-ALL. Bars show means + standard error of the mean (SEM) from 5 independent experiments (the same as those analyzed in Figure 3C), each with a distinct color-coded primary T-ALL; circles represent independent mice. (B) Representative histologic images of FACS-sorted splenic myeloid subsets from primary LN3 T-ALL–transplanted mice, stained with the May-Grünwald Giemsa reagent. Scale bars, 10 μm. (C) Quantification of viable T-ALL cells 6 or 7 days after culture in the presence or absence of the indicated FACS-sorted myeloid subsets from the spleen or liver of transplanted LN3 T-ALL–bearing mice. Bars show means + SEM of cumulative results from 6 to 8 independent experiments, each with a color-coded distinct primary T-ALL; circles represent the average of technical replicate wells per experiment. The red line indicates the mean number of viable T-ALL cells cultured alone. *P < .05, **P < .01, ***P < .001, unpaired Student t test (A), repeated measures 1-way ANOVA with the Bonferroni correction (C). ns, not significant.